A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients
NCT07573332 is a phase 1 interventional trial sponsored by University of Texas Southwestern Medical Center. As of 21 Nov 2026, it is not yet recruiting. It studies CC-97540, Cyclophosphamide, Fludarabine and Tocilizumab in AQP4+ NMOSD. The registry lists an enrollment of 5 participants at 1 site in 1 country. The registry lists a start date of 1 Sept 2026 and a primary completion date of 1 Aug 2030.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT07573332 |
| Status | Not yet recruiting |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | University of Texas Southwestern Medical Center |
| Enrollment | 5 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | AQP4+ NMOSD |
| Drugs | CC-97540, Cyclophosphamide, Fludarabine and Tocilizumab |
| Start | 1 Sept 2026 |
| Primary completion | 1 Aug 2030 |
| Study completion | 1 Aug 2031 |
| Last update posted | 17 Jul 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Benjamin Greenberg, MD
UT Southwestern
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ut Southwestern
Dallas
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT07573332
Each answer restates registry values shown on this page.
What is NCT07573332?
NCT07573332 is a phase 1 interventional trial sponsored by University of Texas Southwestern Medical Center. It studies CC-97540, Cyclophosphamide, Fludarabine and Tocilizumab in AQP4+ NMOSD.
Is NCT07573332 recruiting?
As of 21 Nov 2026, it is not yet recruiting.
Who leads NCT07573332?
The registry names Benjamin Greenberg, MD (principal investigator, UT Southwestern) as the overall official.
Where does NCT07573332 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT07573332 study?
The registered drug and biological interventions are CC-97540, Cyclophosphamide, Fludarabine and Tocilizumab.
When is NCT07573332 expected to complete?
The registry lists a primary completion date of 1 Aug 2030 and a study completion date of 1 Aug 2031. The sponsor last updated the record on 17 Jul 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.